Itraconazole
- Generic Name
- Itraconazole
- Brand Names
- Sporanox, Tolsura
- Drug Type
- Small Molecule
- Chemical Formula
- C35H38Cl2N8O4
- CAS Number
- 84625-61-6
- Unique Ingredient Identifier
- 304NUG5GF4
- Background
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
- Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- Associated Conditions
- Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
- Associated Therapies
- -
Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)
- Conditions
- Interventions
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 144
- Registration Number
- NCT00895453
- Locations
- 🇦🇹
Vienna Medical School, Vienna, Austria
Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 132
- Registration Number
- NCT00871728
Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2009-04-30
- Lead Sponsor
- Javelin Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT00805090
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇬🇧Simbec Research, Ltd., Merthyr Tydfil, United Kingdom
🇺🇸New Orleans Clinical Center for Research, Knoxville, Tennessee, United States
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 13
- Registration Number
- NCT00798135
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections
- Conditions
- Interventions
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 288
- Registration Number
- NCT00794703
Study Comparing SUBA™-Itraconazole With SPORANOX® (Itraconazole) in the Treatment of Onychomycosis
- Conditions
- Interventions
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- Halcygen Pharmaceuticals Limited
- Target Recruit Count
- 175
- Registration Number
- NCT00791219
- Locations
- 🇺🇸
PMG Research, Salisbury, North Carolina, United States
🇺🇸Synergyst Research, Altamonte Springs, Florida, United States
🇺🇸Coastal Carolina Research, Mount Pleasant, South Carolina, United States
An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
- Conditions
- Interventions
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT00787917
- Locations
- 🇬🇧
Novartis Investigator Site, London, United Kingdom
Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2019-02-01
- Target Recruit Count
- 23
- Registration Number
- NCT00769600
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇸🇬Singapore General Hospital, Tiong Bahru Estate, Singapore
Study to Assess Blood Levels of Itraconazole During a Two-Week Period
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Stiefel, a GSK Company
- Target Recruit Count
- 16
- Registration Number
- NCT00695071
- Locations
- 🇺🇸
Advanced Biomedical Research, Hackensack, New Jersey, United States
Assessment of Mechanisms of Improved Wound Healing
- Conditions
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2023-07-03
- Target Recruit Count
- 644
- Registration Number
- NCT00673309
- Locations
- 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.